RecruitingNCT06314113
Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection
Evaluation of Oral Epigallocatechin Gallate Treatment for Low-grade Cervical Lesions (L-SIL) Associated With Human Papilloma Virus (HPV) Infection
Sponsor
University of Palermo
Enrollment
50 participants
Start Date
Mar 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection
Exclusion Criteria6
- Pregnancy
- Concomitant pathologies causing immunosuppression
- Concurrent Immunomodulatory therapies
- Hormone replacement therapy
- High-grade Cervical Lesions (H-SIL) or in situ adenocarcinoma
- Previous history of L-SIL or higher grade lesions ≥ 24 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTEpigallocatechin Gallate
Oral treatment with Epigallocatechin Gallate 200 mg per day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06314113